64Cu-p-NH 2-Bn-DOTA-hu14.18K322A, a PET radiotracer targeting neuroblastoma and melanoma

Journal of Nuclear Medicine

Volumn 53, Issue 11, 2012, Pages 1772-1778

  Vavere, Amy L ^a   Butch, Elizabeth R ^a   Dearling, Jason L J ^b   Packard, Alan B ^b   Navid, Fariba ^a   Shulkin, Barry L ^a   Barfield, Raymond C ^c   Snyder, Scott E ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

64Cu; Antibody; Disialoganglioside GD; Neuroblastoma; Positron emission tomography

Indexed keywords

GANGLIOSIDE GD 1B; GANGLIOSIDE GD2; TETRAXETAN 4 AMIDE MONOCLONAL ANTIBODY HU14.18K322A CU 64; TRACER; UNCLASSIFIED DRUG; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; ANTIBODY; COPPER; DIAGNOSTIC AGENT; GANGLIOSIDE; HYBRID PROTEIN; SIALOGANGLIOSIDES; SINGLE HETEROCYCLIC RINGS; TETRAXETAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG UPTAKE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MELANOMA; MOUSE; NEUROBLASTOMA; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; RADIOCHEMISTRY; ANIMAL; CHEMISTRY; HALF LIFE TIME; HUMAN; IMMUNOLOGY; METABOLISM; METHODOLOGY; PATHOLOGY; SCINTISCANNING; TUMOR CELL LINE;

ANIMALS; ANTIBODIES; CELL LINE, TUMOR; COPPER RADIOISOTOPES; FEMALE; GANGLIOSIDES; HALF-LIFE; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MELANOMA; MICE; NEUROBLASTOMA; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; RECOMBINANT FUSION PROTEINS;

EID: 84868306101     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.104208     Document Type: Article

References (39)

1. Sharp SE, Gelfand MJ, Shulkin BL. Pediatrics: diagnosis of neuroblastoma. Semin Nucl Med. 2011;41:345-353.
2. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3:203-216.
3. Kushner BH. Neuroblastoma: a disease requiring a multitude of imaging studies. J Nucl Med. 2004;45:1172-1188.
4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
5. Cheung NK, Lazarus H, Miraldi FD, et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol. 1987;5:1430-1440.
6. Choi BS, Sondel PM, Hank JA, et al. Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma. Cancer Immunol Immunother. 2006;55:761-774.
7. AlbertiniMR, Hank JA, Schiller JH, et al. Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. Clin Cancer Res. 1997;3:1277-1288.
8. Murray JL, Kleinerman ES, Jia SF, et al. Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocytemacrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. J Immunother Emphasis Tumor Immunol. 1996;19:206-217.
9. Saleh MN, Khazaeli MB, Wheeler RH, et al. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. Hum Antibodies Hybridomas. 1992;3:19-24.
10. Yu AL, Uttenreuther-Fischer MM, Huang CS, et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol. 1998;16:2169-2180.
11. Gilman AL, Ozkaynak MF, Matthay KK, et al. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group. J Clin Oncol. 2009;27:85-91.
12. Handgretinger R, Anderson K, Lang P, et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer. 1995;31A:261-267.
13. Ozkaynak MF, Sondel PM, Krailo MD, et al. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocytemacrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. J Clin Oncol. 2000;18:4077-4085.
14. Modak S, Cheung NK. Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest. 2007;25:67-77.
15. Cheresh DA, Harper JR, Schulz G, Reisfeld RA. Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc Natl Acad Sci USA. 1984;81:5767-5771.
16. Saito M, Yu RK, Cheung NK. Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cell. Biochem Biophys Res Commun. 1985;127:1-7.
17. Saarinen UM, Coccia PF, Gerson SL, Pelley R, Cheung NK. Eradication of neuroblastoma cells in vitro by monoclonal antibody and human complement: method for purging autologous bone marrow. Cancer Res. 1985;45:5969-5975.
18. Mueller BM, Reisfeld RA, Gillies SD. Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2. Proc Natl Acad Sci USA. 1990;87:5702-5705.
19. Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld RA. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res. 1991;51:144-149.
20. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324-1334.
21. Sorkin LS, Otto M, Baldwin WM 3rd, et al. Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia. Pain. 2010;149:135-142.
22. Navid F, Barfield RC, Handgretinger R, et al. A novel anti-GD2 monoclonal antibody (mAb), hu14.18K322A, in children with refractory or recurrent neuroblastoma: early-phase evaluation [abstract]. J Clin Oncol. 2011;29(15 suppl):9523.
23. 64Cu-SarAr immunoconjugates. Proc Natl Acad Sci USA. 2007;104:17489-17493.
24. Vavere AL, Dearling JL, Packard AB, et al. Chelate conjugation and Cu-64 labeling of Hu14.18K322A, an antibody targeting neuroblastoma. J Labelled Comp Radiopharm. 2009;52(suppl 1):S405.
25. 64Cu using a biomedical cyclotron. Nucl Med Biol. 1997;24:35-43.
26. Meares CF, McCall MJ, Reardan DT, Goodwin DA, Diamanti CI, McTigue M. Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem. 1984;142:68-78.
27. Price JE, Barth RF, Johnson CW, Staubus AE. Injection of cells and monoclonal antibodies into mice: comparison of tail vein and retroorbital routes. Proc Soc Exp Biol Med. 1984;177:347-353.
28. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem. 2010;21:797-802.
29. Navid F, Santana VM, Barfield RC. Anti-GD2 antibody therapy for GD2-expressing tumors. Curr Cancer Drug Targets. 2010;10:200-209.
30. Kowalczyk A, Gil M, Horwacik I, Odrowaz Z, Kozbor D, Rokita H. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells. Cancer Lett. 2009;281:171-182.
31. Navid F, Armstrong M, Barfield RC. Immune therapies for neuroblastoma. Cancer Biol Ther. 2009;8:874-882.
32. 18F-FDG PET in neuroblastoma. J Nucl Med. 2009;50:1237-1243.
33. 64Cu-labeled antibody. Nucl Med Biol. 2011;38:29-38.
34. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med. 2010;51:1293-1300.
35. 64Cu for tumor imaging and therapy. J Nucl Med. 2003;44:1284-1292.
36. Bass LA, Wang M, Welch MJ, Anderson CJ. In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. Bioconjug Chem. 2000;11:527-532.
37. Boswell CA, Sun X, Niu W, et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem. 2004;47:1465-1474.
38. Rogers BE, Anderson CJ, Connett JM, et al. Comparison of four bifunctional chelates for radiolabeling monoclonal antibodies with copper radioisotopes: biodistribution and metabolism. Bioconjug Chem. 1996;7:511-522.
39. Schulz G, Cheresh DA, Varki NM, Yu A, Staffileno LK, Reisfeld RA. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res. 1984;44:5914-5920.